Effects of polypharmacy on the safety of anticoagulant treatment in burn patients — a retrospective analysis of clinical cases

The article is devoted to the problem of safety of anticoagulant use in patients with burn injury against the background of polypharmacy. A retrospective analysis of 100 medical records of inpatients in the burn department who received anticoagulants for the prevention of venous thromboembolic complications (VTEC) was conducted for the period from 2022 to 2023, in order to study the safety of using anticoagulants in burn department patients with polypharmacy. According to the analyzed data, in patients taking anticoagulants in prophylactic doses and receiving more than 3 drugs simultaneously, in addition to changes in some clinical and laboratory parameters and coagulogram parameters (a significant increase in the number of blood leukocytes by 18 % (p ≤ 0.002), alanine aminotransferase (ALT) by 61 % (p ≤ 0.0001), aspartate aminotransferase (AST) by 32 % (p ≤ 0.0001), international normalized ratio (INR) by 11 % (p ≤ 0.02), activated partial thromboplastintime (APTT) by 7 % (p ≤ 0.0001), there is an increase in the length of the patient's hospital stay by 7 days (by 85 %, p ≤ 0.00003), compared with those who received less than 3 drugs.